Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCTGNASDAQ:CRMDNASDAQ:OCSNASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTGBCTG Acquisition$10.68$9.83▼$14.00$218.05MN/A36,697 shs2,024 shsCRMDCorMedix$11.30-1.1%$12.57$3.61▼$17.43$766.42M1.581.34 million shs616,537 shsOCSOculis$18.65-0.5%$18.91$10.79▼$23.08$814.30M0.2945,242 shs8,391 shsSNDXSyndax Pharmaceuticals$8.85+1.4%$10.41$8.58▼$25.07$761.54M0.71.84 million shs683,802 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTGBCTG Acquisition0.00%0.00%0.00%0.00%0.00%CRMDCorMedix-1.89%-7.31%-18.31%+68.19%+177.18%OCSOculis-1.13%-3.45%-5.92%+26.62%+60.72%SNDXSyndax Pharmaceuticals-5.89%-6.73%-23.76%-17.33%-58.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTGBCTG AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACRMDCorMedix2.759 of 5 stars4.41.00.00.03.10.00.6OCSOculis1.7491 of 5 stars3.53.00.00.00.60.00.6SNDXSyndax Pharmaceuticals3.1347 of 5 stars3.51.00.04.41.20.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTGBCTG Acquisition 0.00N/AN/AN/ACRMDCorMedix 2.88Moderate Buy$17.1451.71% UpsideOCSOculis 3.00Buy$35.3389.45% UpsideSNDXSyndax Pharmaceuticals 2.90Moderate Buy$35.80304.52% UpsideCurrent Analyst Ratings BreakdownLatest BCTG, SNDX, OCS, and CRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025CRMDCorMedixD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/30/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold6/30/2025CRMDCorMedixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.006/24/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $20.006/23/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.006/20/2025CRMDCorMedixRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$13.00 ➝ $17.005/9/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$28.00 ➝ $33.005/7/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $15.005/6/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.005/6/2025SNDXSyndax PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$16.00 ➝ $17.005/6/2025SNDXSyndax PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTGBCTG AcquisitionN/AN/AN/AN/A$0.23 per shareN/ACRMDCorMedix$82.55M9.28N/AN/A$1.40 per share8.07OCSOculisN/AN/AN/AN/A$1.91 per shareN/ASNDXSyndax Pharmaceuticals$23.68M32.16N/AN/A$3.38 per share2.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTGBCTG Acquisition-$120KN/A0.00N/AN/AN/AN/AN/AN/ACRMDCorMedix-$17.93M$0.2251.3712.02N/A20.81%22.57%17.02%8/13/2025 (Estimated)OCSOculis-$97.43M-$2.64N/AN/AN/A-13,788.70%-92.95%-70.03%8/26/2025 (Estimated)SNDXSyndax Pharmaceuticals-$318.76M-$3.86N/AN/AN/A-757.53%-101.60%-58.41%8/7/2025 (Estimated)Latest BCTG, SNDX, OCS, and CRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025OCSOculis-$0.51-$0.77-$0.26-$0.77$0.22 million$0.32 million5/6/2025Q1 2025CRMDCorMedix$0.25$0.30+$0.05$0.30$38.90 million$39.08 million5/5/2025Q1 2025SNDXSyndax Pharmaceuticals-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTGBCTG AcquisitionN/AN/AN/AN/AN/ACRMDCorMedixN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTGBCTG AcquisitionN/A4.804.80CRMDCorMedixN/A4.213.99OCSOculisN/A4.794.79SNDXSyndax Pharmaceuticals1.535.805.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTGBCTG Acquisition62.44%CRMDCorMedix34.18%OCSOculis22.30%SNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipBCTGBCTG AcquisitionN/ACRMDCorMedix5.30%OCSOculisN/ASNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTGBCTG AcquisitionN/A21.38 millionN/ANot OptionableCRMDCorMedix3067.83 million64.23 millionOptionableOCSOculis243.66 millionN/ANot OptionableSNDXSyndax Pharmaceuticals11086.05 million82.52 millionOptionableBCTG, SNDX, OCS, and CRMD HeadlinesRecent News About These CompaniesSyndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug ApprovalsJuly 8 at 5:18 AM | seekingalpha.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 (c) (4) - MorningstarJuly 3, 2025 | morningstar.comMSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)July 2, 2025 | globenewswire.comSyndax Pharmaceuticals, Inc. (SNDX) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comSNDX Syndax Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comSyndax Pharmaceuticals Inc News (SNDX) - Investing.comJune 26, 2025 | investing.comSyndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia - MorningstarJune 25, 2025 | morningstar.comMSyndax Gets Priority Review for Leukemia Drug ApplicationJune 24, 2025 | marketwatch.comSyndax stock rises after FDA grants Priority Review for cancer drug expansionJune 24, 2025 | investing.comSyndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML TrialJune 24, 2025 | msn.comSyndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid LeukemiaJune 24, 2025 | globenewswire.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 21, 2025 | marketbeat.comSyndax reports publication of revumenib data from BEAT AML trialJune 13, 2025 | msn.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Assenagon Asset Management S.A.June 13, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.7% - Time to Sell?June 12, 2025 | marketbeat.comSyndax Pharma releases new data from its AUGMENT-101 trial of RevuforjJune 12, 2025 | thepharmaletter.comTSyndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025June 12, 2025 | globenewswire.comSyndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025June 12, 2025 | globenewswire.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 5, 2025 | globenewswire.comKura Posts New Data, Secures NDA Acceptance in Acute Myeloid Leukemia Race With SyndaxJune 3, 2025 | biospace.comBSyndax Announces Participation in June Investor ConferencesMay 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCTG, SNDX, OCS, and CRMD Company DescriptionsBCTG Acquisition NASDAQ:BCTGBCTG Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses primarily located in North America and Europe in the biotechnology industry. The company was incorporated in 2020 and is based in San Diego, California.CorMedix NASDAQ:CRMD$11.30 -0.12 (-1.05%) As of 02:52 PM EasternCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Oculis NASDAQ:OCS$18.65 -0.09 (-0.48%) As of 02:34 PM EasternOculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Syndax Pharmaceuticals NASDAQ:SNDX$8.85 +0.12 (+1.37%) As of 02:51 PM EasternSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
